Ependymoma, Recurrent Active Not Recruiting Phase 2 Trials for Larotrectinib (DB14723)

Also known as: Ependymoma Recurrent / Recurrent Ependymoma

IndicationStatusPhase
DBCOND0106575 (Ependymoma, Recurrent)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03213704Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)Treatment